Clinuvel Pharmaceuticals Ltd (Clinuvel) specializes in the development and commercialization of melanocortin-based products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Clinuvel has undertaken several R&D initiatives, including the completion of Phase II study CUV040 and the granting of European Orphan Drug Designation (ODD) for afamelanotide. The company has also completed CUV151 in healthy volunteers and continues with CUV152 and CUV156, with European ODD granted for XP. Clinuvel has commenced recruitment for a Phase III study, CUV105, for vitiligo and is currently conducting a Phase II study, CUV803, for AIS. The company has also announced a clinical program, CUV901, for Parkinson's disease. Additionally, Clinuvel has expanded and is currently conducting an adolescent study, CUV052. The R&D unit of Clinuvel Pharmaceuticals Ltd is the Singapore Research, Development & Innovation Centre. This unit is responsible for the formulation work, increasing awareness of the need for photoprotection, and the prelaunch of Cyacelle Radiant. The unit also focuses on advancing three pharmaceutical products and three PhotoCosmetic lines. The company is mainly focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders. It is pioneering in photomedicine and melanocortin technology, leading to innovative treatments for systemic photoprotection, DNA repair, repigmentation, and CNS conditions. The R&D initiatives include the development of SCENESSE and PRÉNUMBRA for severe disorders, NEURACTHEL for neurological and endocrinological disorders, and non-prescription PhotoCosmetic products for UV and HEV light exposure. The company is also expanding its R&D pipeline with new pharmaceutical formulations and melanocortin technology. In FY2025, the company invested AUD7.4 million in its R&D activities.